◆ mixed
Impact
PhasePhase 2 (registration-intent) with Phase 3 confirmatory trial initiated
Time to marketIf the DENALI Part 2 readout in 1H 2027 is positive, Zentalis plans to discuss an accelerated approval pathway with the FDA in 2027. Under an accelerated approval scenario, a potential FDA decision could come in 2028 at the earliest, though the timeline is uncertain and depends on regulatory feedback.
azenosertib Updated Nov 10
What to watch
The next major catalyst is the DENALI Part 2 topline readout expected in 1H 2027 (roughly 2-7 months away). A positive readout could support an accelerated approval filing with the FDA; a negative or mixed readout would likely devastate the stock given Zentalis is a single-asset company. The August 2026 delay from year-end 2026 to 1H 2027 was a negative signal, and the stock now trades at $1.74, well below the $3.50 August offering price. Monitor FDA discussions in 2027 and any pre-readout data disclosures.
Bull case
- DENALI Part 1b interim overall survival data showed 15.9 months median OS in Cyclin E1-positive platinum-resistant ovarian cancer patients vs 7.5 months in the negative subgroup, a clinically meaningful difference presented at ESMO Congress 2026 (source: Zentalis press release Oct 18, 2026).
- FDA granted Fast Track designation for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer in May 2026, which can expedite development and review (source: FDA catalysts data, May 12, 2026).
- Analyst consensus is strongly bullish: 7 Strong Buy, 6 Buy, 4 Hold, 0 Sell, with a mean price target of $7.33, implying roughly 321% upside from the $1.74 close.
Bear case
- DENALI Part 2 topline readout was delayed from year-end 2026 to 1H 2027, pushing back the regulatory timeline and signaling potential execution risk (source: Zentalis Q3 2026 8-K filed Nov 9, 2026).
- The August 2026 follow-on offering of 26.45M shares at $3.50/share diluted existing holders by roughly 27% and the stock now trades at $1.74, below the offering price (source: SEC filing Aug 14, 2026; stock price $1.74 as of Nov 9, 2026).
- As a pre-revenue clinical-stage biotech with no approved products, Zentalis has ongoing operating losses (Q3 2026 net loss of $28.8M) and depends entirely on azenosertib's success (source: Zentalis Q3 2026 8-K).